Management

Show all
Robert B. Jones
President & Chief Executive Officer
Bob has been our President & CEO since July 2011 and served in that capacity on an interim basis since May 2011 after the passing of Andy Reddick in April 2011. Bob previously served as Senior Vice President and Chief Operating Officer since he joined Acura in April 2008. From May, 2003 to March, 2008, Mr. Jones served first as the Vice President, Finance and then as Vice President, Strategy and Business Analysis of Adolor Corporation. From November 2000 to May, 2003 he served as Vice President, Finance and then as Chief Operating Officer of Opt-E-Script, Inc., a privately held personalized medicine company where Mr. Jones was responsible for all commercialization activities. Prior to that, Mr. Jones was Vice President, Sales and Marketing for Purepac Pharmaceutical Company. Mr. Jones received his M.B.A. from the University of North Carolina and a B.S. from Cornell University.
    Peter A. Clemens
    Senior Vice President, Chief Financial Officer
    Pete has been Senior Vice President, Chief Financial Officer and Secretary since April 2004. Mr. Clemens was our Vice President, Chief Financial Officer and Secretary from February 1998 to March 2004 and a member of our Board of Directors from June, 1998 to August, 2004. Mr. Clemens is a Certified Public Accountant and earned a Bachelor of Business Administration degree from the University of Notre Dame and a Masters of Business Administration from Indiana University.
      James F. Emigh R.PH.
      Vice President, Corporate Development
      Jim has been Vice President, Corporate Development since October 2011. Prior to that, Mr. Emigh was our Vice President of Marketing and Administration from April 2004 through September 2011. Mr. Emigh joined the company in May, 1998, serving first as Executive Director of Customer Relations, then as Vice President of Operations until November, 2002, and as Vice President of Sales and Marketing until March 2004. Mr. Emigh holds a Bachelor of Pharmacy degree from Washington State University and a Masters of Business Administration from George Mason University.
        Robert A. Seiser CPA
        Vice President, Treasurer and Corporate Controller
        Bob has been Vice President, Treasurer and Corporate Controller since April 2004. Mr. Seiser joined us in March 1998 as our Treasurer and Corporate Controller. Mr. Seiser is a Certified Public Accountant and earned a Bachelor of Business Administration degree from Loyola University of Chicago.
          Albert W. Brzeczko Ph.D.
          Vice President, Technical Affairs

          Al has been Vice President, Technical Affairs of Acura Pharmaceutical Technologies, Inc. since February 2009. From 1999 through 2009, Dr. Brzeczko was Vice President, Global Pharma New Product Development and Pharma Technologies for International Specialty Products, Inc., a contract services group specializing in the development of technologies for the bioenhancement of poorly soluble drugs. Prior to 1999, Dr. Brzeczko held various positions of increasing responsibility in pharmaceutical product development with UPM Pharmaceuticals, Banner Pharmacaps, Mylan Laboratories, and DuPont Merck. Dr. Brzeczko received a Bachelor of Science degree in biochemistry and a Ph.D. in pharmaceutical sciences from the University of Maryland.

            Ronald L. Leech
            Senior Director Quality & Analytical Chemistry

            Ron has been the Senior Director Quality & Analytical Chemistry of Acura Pharmaceutical Technologies, Inc. since May 2004. Prior to that time he was Director of Analytical Chemistry. Ron's current responsibilities include leadership of the Company's programs for analytical method development and validation, quality control, quality assurance and product stability testing. Prior to joining the company in April 2002 Ron held positions at ILEX Oncology, DPT Laboratories and PPD/Pharmaco. His background includes biopharmaceutical oncology, development of novel dermatological products for use in the field of burn management, contract manufacturing, contract analytical services, and medical devices. Ron holds a BS degree in Biochemistry from Edgewood College in Madison, WI.

              John G. Gilkay P.E.
              Director of EHS & Engineering

              John has been the Director of EHS & Engineering of Acura Pharmaceutical Technologies, Inc. since April 2004. Prior to that time, he was Director Environmental Affairs, Health and Safety at our Culver, Indiana facility. From September 1993 until joining the Company in April 2000 he was employed by Laidlaw Environmental Services/Safety-Kleen managing environmental multimedia, health and safety, and transportation compliance for several facilities in Southern California. John has also held positions with Johnson & Johnson, Merck CPC, W.R. Grace and Angus Biotech in a variety of production, engineering and EHS compliance roles. He is a licensed Professional Engineer and holds a B.S. degree in Chemical Engineering from the University of Wisconsin..

                Gregory A. Spinner
                Director of Logistics and Special Projects

                Greg has been Director of Logistics and Special Projects of Acura Pharmaceutical Technologies, Inc. since April 2004. Prior to that time he served the Company as Director of Supply Chain Management and Financial Controller for operations facilities. Prior to joining the Company in August 1998 Greg was employed by Transfer Drivers, Inc. and Morgan Drive Away, Inc. as an Accountant and Divisional Controller. Greg holds a BA degree in Accounting from Western Michigan University.

                  Stock transaction information provided by EDGAR Online. Acura Pharmaceuticals, Inc. makes no representation or warranty with respect to any of the information contained herein, takes no responsibility for supplementing, updating or correcting any such information and shall have no liability with respect to any such information. This listing does not include derivatives, such as stock option grants or shares purchased through an employee stock purchase plan. For recent transactions, including derivative transactions, see our Section 16 SEC filings page.